Therapeutic immunization for the control of HIV-1: Where are we now?

International Journal of STD and AIDS

Volumn 17, Issue 7, 2006, Pages 436-442

  Dorrell, Lucy ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Clinical trial; HAART; HIV 1; T cell response; Vaccine

Indexed keywords

ANTIGEN P24; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; LIPOPEPTIDE; PROTEIN P17; RECOMBINANT GP160 VACCINE; RECOMBINANT VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

CANARYPOX VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LONG TERM CARE; MAINTENANCE THERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; VACCINATION; VIRUS LOAD; VIRUS RESISTANCE;

AIDS VACCINES; ANIMALS; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; VACCINES, DNA;

EID: 33745882945     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206777689035     Document Type: Review

References (60)

1. Palella Jr F, Delaney K, Moorman A. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60
2. Mocroft A, Ledergarber B, Katloma C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-9
3. Marins J, Jamal L, Chen S, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003;17:1675-82
4. Wong JK, Hezarel M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5
5. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30
6. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ Tcell homeostasis and function in advanced HIV disease. Science 1997; 277:112-16
7. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004;305:205-8
8. Koup R, Safrit J, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-5
9. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003;100:4144-9
10. McMichael A, Rowland-Jones S. Cellular immune responses to HIV. Nature 2001;410:980-7
11. Schmitz JE, Kuroda MJ, Santra S, et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003;77:2165-73
12. Douek DC, Brenchlay JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002;417:95-8
13. McNeil AC, Shupert WL, Iyasere CA, et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4+ T cell proliferation. Proc Natl Acad Sci USA 2001;98:13878-83
14. Migueles SA, Laborico AC, Shupart WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002;3:1061-8
15. Phillips R, Rowland-Jones S, Nixon D, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:453-9
16. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73:797-800
17. Pitcher C, Quittner C, Peterson D, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999;5:518-25
18. Oxenius A, Price DA, Gunthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002;99:13747-52
19. Kaufmann DE, Lichterfeld M, Altfield M, et al. Limited durability of viral control following treated acute hiv infection. PLoS Med 2004;1:e36
20. Davenport MP, Ribeiro RM, Perelson AS. Kinetics of virusspecific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol 2004;78:10096-103
21. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ Tcell responses associated with control of viremia. Science 1997;278:1447-50
22. Younes S, Yassine-Diab B, Dumont A, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003;198:1909-22
23. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 gag-specific IFN-{gamma}+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infecti. J Immunol 2002;169:6376-85
24. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004;103:966-72
25. Redfield R, Birx D, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. military medical consortium for applied retroviral research. N Engl J Med 1991;324:1677-84
26. Birx D, Loomis-Price L, Aronson N, et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 phase II vaccine investigators. J Infect Dis 2000;181:881-9
27. Kundu S, Katzenstein D, Moses L, Merigan T. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc Natl Acad Sci USA 1992;89:11204-8
28. Goebel F, Mannhalter J, Belshe R, et al. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. AIDS 1999;13:1461-8
29. Veenstra J, Williams S, Colebunders R, et al. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis 1996;174:862-6
30. Kelleher A, Roggensack M, Jaramillo A, et al. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. AIDS 1998;12:175-82
31. Lindenburg CEA, Stolte I, Langendam MW, et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 2002;20:2343-7
32. Moss R, Giermakowska W, Savary J, et al. A primer on HIV type 1-specific immune function and REMUNE. AIDS Res Hum Retrov 1998;14:S167-75
33. Kahn JO, Cherng DW, Mayer K, et al. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts: a randomized controlled trial. JAMA 2000;284:2193-202
34. Robbins GK, Addo M, Troung H, et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 2003;17:1121-6
35. Tryniszewska E, Nacsa J, Lewis MG, et al. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol 2002;169:5347-57
36. Clements-Mann M-L, Weinhold K, Matthews T. Immune responses to human immunodeficiency virus type 1 (HIV-1) induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998;177:1230-46
37. Belshe R, Stevens C, Gorse G. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase II study in higher- and lower-risk volunteers. J Infect Dis 2001;183:1343-52
38. Tubiana R, Carcelain G, Vray M, et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type-1-recombinant canarypox vaccine in chronically HIV-1 infected patients. The Vacciter study (ANRS 094). Vaccine 2005;23:4292-301
39. Levy Y, Gahery-Segard H, Durier C, et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005;19:279-86
40. Jin X, Ramanathan Jr M, Barsoum S, et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 2002;76:2206-16
41. Markowitz M, Jin X, Hurley M, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002;186:634-43
42. Kinloch S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 vireamia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005;192:607-17
43. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-7
44. Cosma A, Nagaraj R, Buhler S, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003;22:21-9
45. Harrer E, Bäuerle M, Ferstl B, et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 2005;10:285-300
46. Dorrell L, Yang H, Ondondo B, et al. Expansion and diversification of virus-specific T cells following immunisation of HIV-1 infected individuals with a recombinant modified vaccinia virus. Ankara/HIV-1 gag vaccine. J Virol 2006;80, in press
47. Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional HIV-1 specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA - and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8+ T cell epitopes. J Virol 2006;8, in press
48. McConkey S, Reece W, Morthy V, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003;9:729-35
49. Mwau M, Cebere I, Sutton J, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004;85:911-19
50. Barouch D, Santra S, Schmitz J. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-92
51. MacGregor R, Boyer J, Ugen K, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998;178:92-100
52. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998;351:1320-5
53. Dorrell L, Yang H, Iversen A, et al. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/polyepitope DNA vaccine. AIDS 2005, (in press)
54. Radaelli A, Nacsa J, Tsai WR, et al. Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. Virology 2003;312:181-95
55. Lisziewicz J, Trocio J, Xu J, et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 2005;19:35-43
56. Lu W, Wu X, Lu Y, Guo W, Andrieu J. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003;9:27-32
57. Lu W, Arraes LC, Ferreira WT, Andrieu J-M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004;10:1359-65
58. Garcia F, Lejeune M, Climent N, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005;191:1680-5
59. Rosati M, von Gegerfelt A, Roth P, et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 2005;79:8480-92
60. Boyer JD, Robinson TM, Kutzler MA, et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 2005;34:262-70